ET
TVTX icon

Entropy Technologies’s Travere Therapeutics TVTX Stock Holding History

Entropy Technologies’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$697K Buy
23,464
+1,263
+6% +$37.8K 0.03% 514
2025
Q4 		$848K Buy
22,201
+5,408
+32% +$176K 0.05% 424
2025
Q3 		$401K Buy
+16,793
New +$316K 0.03% 580
2025
Q2 		– Sell
-14,592
Closed -$261K – 1024
2025
Q1 		$261K Buy
14,592
+2,292
+19% +$46.5K 0.03% 569
2024
Q4 		$214K Buy
+12,300
New +$218K 0.02% 625
2024
Q1 		– Sell
-27,838
Closed -$250K – 874
2023
Q4 		$250K Buy
+27,838
New +$203K 0.05% 477

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Entropy Technologies's TVTX Position: Q1 2026 in Review

Entropy Technologies increased its Travere Therapeutics (TVTX) stake by 5.7% in Q1 2026, buying an estimated $37.8K and bringing the position to 23,464 shares worth $697K. The position accounts for 0.03% of the portfolio, ranked #514.

Entropy Technologies first reported a position in TVTX in Q4 2023 and has held it in 6 quarters since. The position peaked at $848K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Entropy Technologies held 23,464 shares of Travere Therapeutics worth $697K as of Q1 2026.
  • Entropy Technologies bought 1,263 Travere Therapeutics shares in Q1 2026, an estimated $37.8K.
  • Travere Therapeutics made up 0.03% of Entropy Technologies's portfolio in Q1 2026, its #514 holding.
  • Entropy Technologies first reported a position in Travere Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • Entropy Technologies's Travere Therapeutics position peaked at $848K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.